Same Indication

Lutetium Oxodotreotide Lu-177 vs Pembrolizumab

Lutetium Oxodotreotide Lu-177 vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Lutetium Oxodotreotide Lu-177 and Pembrolizumab.

Mechanism of Action

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Pembrolizumab — 26 days.

Chemical Properties

Type: Lutetium Oxodotreotide Lu-177 — Protein; Pembrolizumab — Antibody.